Abstract
|
Interference of Daratumumab Treatment in the Biological Monitoring of Multiple Myeloma
by O. Skalante, Y. Eddair, Z. Elidrissi, C. Echiguer, R. Bella-Tedga, A. Biaz, S. Bouhsain, H. Elmaaroufi, A. Dami, S. El-Machtani-Idrissi
|
|
|
Background: Multiple myeloma is a plasma cell malignancy characterized by monoclonal immunoglobulin production. Daratumumab has improved therapeutic outcomes but can interfere with laboratory assessments.
Methods: A 73-year-old woman with IgG kappa multiple myeloma achieved remission after initial treatment, then relapsed and received DRD. A monoclonal IgG kappa spike was observed on follow-up SPEP and IFE.
Results: Daratumumab, due to its IgG1 kappa structure, may mimic disease-related monoclonal proteins, potentially leading to false detection of residual disease and misclassification of complete response as very good partial response.
Conclusions: Recognizing such interference and ensuring strong clinician-biologist collaboration is essential for accurate response interpretation.
DOI: 10.7754/Clin.Lab.2025.250510
|
